Profile change history

What changed for Amycretin?

A deterministic history of records added to PeptideScanner and preserved profile or record revisions connected through the reviewed Amycretin identity.

12Total events
9Record additions
3Version changes
2Cited source years

Before and after

Preserved version changes

Profile updated

Amycretin profile

We added the six Novo Nordisk Phase 3 trials that ClinicalTrials.gov lists under the name zenagamtide, which the previous version did not describe, from registry records PeptideScanner retained on November 15, 2026.

PeptideScanner change date
November 15, 2026
Evidence lane
Profile

Profile summary

Before
An experimental Novo Nordisk GLP-1 and amylin receptor agonist, now named zenagamtide. It is not FDA-approved.
After
An experimental Novo Nordisk GLP-1 and amylin receptor agonist, now named zenagamtide and in registered Phase 3 trials. It is not FDA-approved.

Evidence note

Before
Published randomized trials, each with fewer than 300 participants, report weight loss in early studies and lower HbA1c in a Phase 2 diabetes trial, with common gastrointestinal side effects.
After
Published randomized trials, each with fewer than 300 participants, report weight loss in early studies and lower HbA1c in a Phase 2 diabetes trial, with common gastrointestinal side effects. Phase 3 trials registered as zenagamtide have not reported results.

Cited source records

Before
ctg-nct06049329-v6, journal-pmid-40550229, journal-pmid-40550231, journal-pmid-42532080
After
ctg-nct06049329-v6, journal-pmid-40550229, journal-pmid-40550231, journal-pmid-42532080, ctg-observation-nct07668401-2026-08-24-5833a93b62ac, ctg-observation-nct07720271-2026-09-28-93ed8b5caeb7, ctg-observation-nct07797335-2026-09-01-bc9e4b3246b2, ctg-observation-nct07861100-2026-10-06-c1032ee418d6, ctg-observation-nct07931495-2026-11-12-23a664ffa2bf, ctg-observation-nct07931547-2026-11-12-2d2f13db63aa

Claim citations

Before
name: ctg-nct06049329-v6; aliases: ctg-nct06049329-v6, journal-pmid-42532080; category: ctg-nct06049329-v6; status: ctg-nct06049329-v6, journal-pmid-42532080; summary: ctg-nct06049329-v6, journal-pmid-42532080; evidenceNote: journal-pmid-40550229, journal-pmid-40550231, journal-pmid-42532080
After
name: ctg-nct06049329-v6; aliases: ctg-nct06049329-v6, journal-pmid-42532080; category: ctg-nct06049329-v6; status: ctg-nct06049329-v6, journal-pmid-42532080; summary: ctg-nct06049329-v6, journal-pmid-42532080, ctg-observation-nct07668401-2026-08-24-5833a93b62ac, ctg-observation-nct07720271-2026-09-28-93ed8b5caeb7, ctg-observation-nct07797335-2026-09-01-bc9e4b3246b2, ctg-observation-nct07861100-2026-10-06-c1032ee418d6, ctg-observation-nct07931495-2026-11-12-23a664ffa2bf, ctg-observation-nct07931547-2026-11-12-2d2f13db63aa; evidenceNote: journal-pmid-40550229, journal-pmid-40550231, journal-pmid-42532080, ctg-observation-nct07668401-2026-08-24-5833a93b62ac, ctg-observation-nct07720271-2026-09-28-93ed8b5caeb7, ctg-observation-nct07797335-2026-09-01-bc9e4b3246b2, ctg-observation-nct07861100-2026-10-06-c1032ee418d6, ctg-observation-nct07931495-2026-11-12-23a664ffa2bf, ctg-observation-nct07931547-2026-11-12-2d2f13db63aa
Profile status changed

Amycretin profile

We added a plain-language reader guide with cited answers, published trial results from our human evidence review, and the 2026 report that renames amycretin zenagamtide.

PeptideScanner change date
November 14, 2026
Evidence lane
Profile

Status

Before
Investigational
After
In clinical trials; not FDA-approved

Profile summary

Before
An amylin and GLP-1 receptor agonist candidate. This profile cites a completed ClinicalTrials.gov study record.
After
An experimental Novo Nordisk GLP-1 and amylin receptor agonist, now named zenagamtide. It is not FDA-approved.

Evidence note

Before
ClinicalTrials.gov lists a Novo Nordisk oral amycretin study as completed, last updated March 5, 2025.
After
Published randomized trials, each with fewer than 300 participants, report weight loss in early studies and lower HbA1c in a Phase 2 diabetes trial, with common gastrointestinal side effects.

Related names

Before
None recorded
After
Zenagamtide

Cited source records

Before
ctg-nct06049329-v6
After
ctg-nct06049329-v6, journal-pmid-40550229, journal-pmid-40550231, journal-pmid-42532080

Claim citations

Before
name: ctg-nct06049329-v6; aliases: ctg-nct06049329-v6; category: ctg-nct06049329-v6; status: ctg-nct06049329-v6; summary: ctg-nct06049329-v6; evidenceNote: ctg-nct06049329-v6
After
name: ctg-nct06049329-v6; aliases: ctg-nct06049329-v6, journal-pmid-42532080; category: ctg-nct06049329-v6; status: ctg-nct06049329-v6, journal-pmid-42532080; summary: ctg-nct06049329-v6, journal-pmid-42532080; evidenceNote: journal-pmid-40550229, journal-pmid-40550231, journal-pmid-42532080
Profile updated

Amycretin profile

We rewrote the profile summary to describe the cited study record more directly. The cited source and status did not change.

PeptideScanner change date
July 27, 2026
Evidence lane
Profile

Profile summary

Before
An amylin and GLP-1 receptor agonist candidate represented in ClinicalTrials.gov.
After
An amylin and GLP-1 receptor agonist candidate. This profile cites a completed ClinicalTrials.gov study record.

Collection chronology

Evidence added to PeptideScanner

Browse all 9 connected records →

Showing the latest 9 additions by PeptideScanner publication date; the complete connected record set remains available on the cross-source timeline. Most recent addition: November 15, 2026.

Record added

ClinicalTrials.gov record NCT07668401

PeptideScanner retained ClinicalTrials.gov record NCT07668401 at 2026-11-15T17:43:02.409Z. Its registry update date was 2026-08-24, and PeptideScanner's reviewed identity mapping was amycretin.

PeptideScanner change date
November 15, 2026
Cited source date
August 24, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT07720271

PeptideScanner retained ClinicalTrials.gov record NCT07720271 at 2026-11-15T17:43:02.409Z. Its registry update date was 2026-09-28, and PeptideScanner's reviewed identity mapping was amycretin.

PeptideScanner change date
November 15, 2026
Cited source date
September 28, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT07797335

PeptideScanner retained ClinicalTrials.gov record NCT07797335 at 2026-11-15T17:43:02.409Z. Its registry update date was 2026-09-01, and PeptideScanner's reviewed identity mapping was amycretin.

PeptideScanner change date
November 15, 2026
Cited source date
September 1, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT07861100

PeptideScanner retained ClinicalTrials.gov record NCT07861100 at 2026-11-15T17:43:02.409Z. Its registry update date was 2026-10-06, and PeptideScanner's reviewed identity mapping was amycretin.

PeptideScanner change date
November 15, 2026
Cited source date
October 6, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT07931495

PeptideScanner retained ClinicalTrials.gov record NCT07931495 at 2026-11-15T17:43:02.409Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was amycretin.

PeptideScanner change date
November 15, 2026
Cited source date
November 12, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT07931547

PeptideScanner retained ClinicalTrials.gov record NCT07931547 at 2026-11-15T17:43:02.409Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was amycretin.

PeptideScanner change date
November 15, 2026
Cited source date
November 12, 2026
Evidence lane
Clinical trials
Record added

PubMed record PMID 40550229

PeptideScanner retained PubMed bibliographic metadata for PMID 40550229 at 2026-07-30T18:25:48.707Z. PubMed recorded a metadata revision date of 2025-07-14 and an Entrez history date of 2025-06-23. PeptideScanner associated this retained record with the identity slug amycretin. These dates describe PubMed metadata history, not the article's original publication date.

PeptideScanner change date
August 10, 2026
Cited source date
July 14, 2025
Evidence lane
Literature metadata
Record added

PubMed record PMID 40550231

PeptideScanner retained PubMed bibliographic metadata for PMID 40550231 at 2026-07-30T18:25:48.707Z. PubMed recorded a metadata revision date of 2025-07-14 and an Entrez history date of 2025-06-23. PeptideScanner associated this retained record with the identity slug amycretin. These dates describe PubMed metadata history, not the article's original publication date.

PeptideScanner change date
August 10, 2026
Cited source date
July 14, 2025
Evidence lane
Literature metadata
Record added

PubMed record PMID 40550232

PeptideScanner retained PubMed bibliographic metadata for PMID 40550232 at 2026-07-30T18:22:52.359Z. PubMed recorded a metadata revision date of 2025-09-11 and an Entrez history date of 2025-06-23. PeptideScanner associated this retained record with the identity slug amycretin. These dates describe PubMed metadata history, not the article's original publication date.

PeptideScanner change date
August 10, 2026
Cited source date
September 11, 2025
Evidence lane
Literature metadata